| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY 10010;
Transplantation Immunology Unit,
Department of Community Medicine, and
Central Clinical Chemistry Laboratory, Geneva University Hospital, Geneva, Switzerland; and
¶ Department of Medical Biochemistry, University Medical Center, Geneva, Switzerland
This open-labeled phase I study provides the first demonstration of the immunogenicity of a precisely defined synthetic polyoxime malaria vaccine in volunteers of diverse HLA types. The polyoxime, designated (T1BT*)4-P3C, was constructed by chemoselective ligation, via oxime bonds, of a tetrabranched core with a peptide module containing B cell epitopes and a universal T cell epitope of the Plasmodium falciparum circumsporozoite protein. The triepitope polyoxime malaria vaccine was immunogenic in the absence of any exogenous adjuvant, using instead a core modified with the lipopeptide P3C as an endogenous adjuvant. This totally synthetic vaccine formulation can be characterized by mass spectroscopy, thus enabling the reproducible production of precisely defined vaccines for human use. The majority of the polyoxime-immunized volunteers (7/10) developed high levels of anti-repeat Abs that reacted with the native circumsporozoite on P. falciparum sporozoites. In addition, these seven volunteers all developed T cells specific for the universal epitope, termed T*, which was originally defined using CD4+ T cells from protected volunteers immunized with irradiated P. falciparum sporozoites. The excellent correlation of T*-specific cellular responses with high anti-repeat Ab titers suggests that the T* epitope functioned as a universal Th cell epitope, as predicted by previous peptide/HLA binding assays and by immunogenicity studies in mice of diverse H-2 haplotypes. The current phase I trial suggests that polyoximes may prove useful for the development of highly immunogenic, multicomponent synthetic vaccines for malaria, as well as for other pathogens.
This article has been cited by other articles:
|
|
 |
|
  I. Bettahi, A. B. Nesburn, S. Yoon, X. Zhang, A. Mohebbi, V. Sue, A. Vanderberg, S. L. Wechsler, and L. BenMohamed Protective Immunity against Ocular Herpes Infection and Disease Induced by Highly Immunogenic Self-Adjuvanting Glycoprotein D Lipopeptide Vaccines Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4643 - 4653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Calvo-Calle, G. A. Oliveira, C. O. Watta, J. Soverow, C. Parra-Lopez, and E. H. Nardin A Linear Peptide Containing Minimal T- and B-Cell Epitopes of Plasmodium falciparum Circumsporozoite Protein Elicits Protection against Transgenic Sporozoite Challenge Infect. Immun., December 1, 2006; 74(12): 6929 - 6939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Dunachie, M. Walther, J. E. Epstein, S. Keating, T. Berthoud, L. Andrews, R. F. Andersen, P. Bejon, N. Goonetilleke, I. Poulton, et al. A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge. Infect. Immun., October 1, 2006; 74(10): 5933 - 5942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Parra-Lopez, J. M. Calvo-Calle, T. O. Cameron, L. E. Vargas, L. M. Salazar, M. E. Patarroyo, E. Nardin, and L. J. Stern Major Histocompatibility Complex and T Cell Interactions of a Universal T Cell Epitope from Plasmodium falciparum Circumsporozoite Protein J. Biol. Chem., May 26, 2006; 281(21): 14907 - 14917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, A. Issagholian, E. A. Berg, J. B. Fishman, A. B. Nesburn, and L. BenMohamed Th-Cytotoxic T-Lymphocyte Chimeric Epitopes Extended by N{varepsilon}-Palmitoyl Lysines Induce Herpes Simplex Virus Type 1-Specific Effector CD8+ Tc1 Responses and Protect against Ocular Infection J. Virol., December 15, 2005; 79(24): 15289 - 15301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Calvo-Calle, G. A. Oliveira, and E. H. Nardin Human CD4+ T Cells Induced by Synthetic Peptide Malaria Vaccine Are Comparable to Cells Elicited by Attenuated Plasmodium falciparum Sporozoites J. Immunol., December 1, 2005; 175(11): 7575 - 7585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Oliveira, K. Wetzel, J. M. Calvo-Calle, R. Nussenzweig, A. Schmidt, A. Birkett, F. Dubovsky, E. Tierney, C. H. Gleiter, G. Boehmer, et al. Safety and Enhanced Immunogenicity of a Hepatitis B Core Particle Plasmodium falciparum Malaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial Infect. Immun., June 1, 2005; 73(6): 3587 - 3597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Nardin, G. A. Oliveira, J. M. Calvo-Calle, K. Wetzel, C. Maier, A. J. Birkett, P. Sarpotdar, M. L. Corado, G. B. Thornton, and A. Schmidt Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes Infect. Immun., November 1, 2004; 72(11): 6519 - 6527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Sieling, W. Chung, B. T. Duong, P. J. Godowski, and R. L. Modlin Toll-Like Receptor 2 Ligands as Adjuvants for Human Th1 Responses J. Immunol., January 1, 2003; 170(1): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Birkett, K. Lyons, A. Schmidt, D. Boyd, G. A. Oliveira, A. Siddique, R. Nussenzweig, J. M. Calvo-Calle, and E. Nardin A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts Infect. Immun., December 1, 2002; 70(12): 6860 - 6870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Caro-Aguilar, A. Rodriguez, J. M. Calvo-Calle, F. Guzman, P. De la Vega, M. Elkin Patarroyo, M. R. Galinski, and A. Moreno Plasmodium vivax Promiscuous T-Helper Epitopes Defined and Evaluated as Linear Peptide Chimera Immunogens Infect. Immun., July 1, 2002; 70(7): 3479 - 3492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Moorthy and A. V S Hill Malaria vaccines Br. Med. Bull., July 1, 2002; 62(1): 59 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ada Vaccines and Vaccination N. Engl. J. Med., October 4, 2001; 345(14): 1042 - 1053. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
